Schedule your call

Case Study: Due Diligence Audit for a US Biotech Investor Evaluating a European Acquisition

GMP Bridge Content Team

12.03.2026

Case Study

Case Study Overview

For investors in biotech and biopharma, a Due Diligence Audit is essential to uncover hidden GMP and operational risks before acquisitions. Weak Quality Systems or unresolved compliance issues can significantly impact valuation and future scalability. This case study shows how GMP Bridge supported a U.S.-based biotech investor with an independent GMP due diligence audit of a European sterile biologics manufacturer, delivering clarity for investment decisions and negotiation leverage.

The Challenge

An U.S.-based biotech investor evaluating the acquisition of a European sterile biologics manufacturer required an independent, expert-led GMP due diligence audit. The goal was to uncover hidden risks, assess regulatory and operational maturity, and provide a clear picture of remediation needs and future scalability before finalizing the deal.

Solution Delivered

GMP Bridge conducted a comprehensive technical due diligence audit to assess regulatory risks, operational performance, and compliance maturity of the target company prior to acquisition.

Comprehensive Onsite Due Diligence Audit

Conducted an in-depth onsite audit covering Quality Systems, manufacturing operations, and supply chain performance.

Inspection History & Compliance Review

Reviewed regulatory inspection history, deviation and CAPA processes, as well as contamination control practices.

Operational Performance Assessment

Evaluated batch release performance, Quality Oversight structures, and the sterility assurance framework.

Risk & Liability Identification

Identified hidden liabilities, remediation requirements, and potential regulatory vulnerabilities impacting acquisition risk.

Due Diligence Report & Remediation Roadmap

Delivered a detailed due diligence report including risk categorization, estimated remediation costs, and post-acquisition priorities.

Integration into Transaction Strategy

Collaborated directly with legal and financial teams to integrate technical findings into valuation models and negotiation strategies.

Impact and Results

The mock inspection program delivered immediate improvements in inspection readiness, regulatory awareness, and cross-functional alignment across both manufacturing sites.

Transparent Risk Profile

Delivered a clear operational and regulatory risk profile of the target company based on a comprehensive quality and manufacturing assessment.

Identification of Hidden Liabilities

Uncovered critical compliance gaps and remediation costs that could impact acquisition valuation and post-deal risk exposure.

Informed Investment Decision-Making

Enabled investors to make well-informed acquisition decisions and strengthened their negotiation leverage during the transaction process.

Strategic Post-Acquisition Roadmap

Provided targeted recommendations for post-acquisition integration, remediation priorities, and operational improvements.

Need an expert GMP perspective to guide your next acquisition or investment?

Schedule your Call

Company Details

  • Region: United States / Europe
  • Company: US-based biotech investor
  • Products: Recombinant proteins and sterile intermediates

Ready to talk the specifics?
So Are we - Get in Touch

  • (+49) 174 957 5861
  • contact@gmpbridge.com

Last Case Studies